Stem cells targeted radioimmunotherapy of acute myelogenous leukemia with 211At-labeled anti-CXCR4 monoclonal antibody

Conclusions: Stem cells-targeted α-particle therapy with 211At-CXCR4 mAb is promising for AML , because absorbed dose delivered to target cells to normal organs would be high enough based on the dosimetry evaluation using tumor xenograft and sphere model. Acknowledgements: This study was financially supported by JSPS KAKENHI Grant Number JP16H05393.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Oncology & amp; Translational (Poster Session) Source Type: research